Dongxiang Zheng

Papers

Total Citations

H-Index

About

Dr. Dongxiang Zheng is a leading urological researcher whose work centers on advancing the management of benign prostatic hyperplasia (BPH) and its associated lower urinary tract symptoms (LUTS). His primary contributions lie in developing and evaluating integrated treatment strategies that bridge pharmacological therapies, minimally invasive surgical therapies (MISTs), and emerging interventional techniques. Dr. Zheng’s 2025 paper, "Integrated management strategies for benign prostatic hyperplasia," has already garnered 3 citations, reflecting its timely relevance in a field where patient-centered, multimodal approaches are increasingly prioritized. His research systematically compares the efficacy and safety of traditional surgeries with newer, less invasive options, providing clinicians with evidence-based frameworks to tailor treatments to individual patient profiles. By synthesizing data on combination therapies and MISTs, Dr. Zheng has helped clarify optimal care pathways for aging men, directly impacting clinical decision-making and quality of life outcomes. His work is particularly notable for its practical focus on integrating diverse modalities—from medical management to advanced procedures—into cohesive, personalized care plans. For students and researchers, Dr. Zheng’s contributions underscore a critical shift toward holistic, minimally invasive urological care, making him a key voice in the evolution of BPH treatment.